Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT ID: NCT00884741

Last Updated: 2019-07-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 637 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-15
• Study Completion Date: 2013-03-17

Brief Summary

This randomized phase III trial studies temozolomide (TMZ) and radiation therapy (RT) to compare how well they work with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may find tumor cells and help kill them. It is not yet known whether temozolomide and radiation therapy are more effective when given together with or without bevacizumab in treating glioblastoma or gliosarcoma.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine whether the addition of bevacizumab to temozolomide and radiation improves efficacy as measured by progression-free and/or overall survival.

II. To assess the association between overall survival and K^trans change from T1 to T2. (ACRIN 6686) III. To assess the association between overall survival and spin echo cerebral blood volume (CBV) change from T1 to T2. (ACRIN 6686)

SECONDARY OBJECTIVES:

I. To determine whether the tumor molecular profile conferring a mesenchymal/angiogenic phenotype is associated with a selective increase in benefit, as measured by either overall survival or progression-free survival, from the addition of bevacizumab.

II. To compare and record the toxicities of the conventional and bevacizumab-containing regimens.

III. To assess the association between progression-free survival and K^trans change from T1 to T2. (ACRIN 6686) IV. To assess the association between progression-free survival and spin echo CBV change from T1 to T2. (ACRIN 6686) V. To assess the association between values of K^trans and spin echo CBV measured separately at T0 and at T1, and overall and progression-free survival. (ACRIN 6686) VI. To assess the association between overall survival and K^trans changes from T0 to T1 and from T2 to T3. (ACRIN 6686) VII. To assess the association between overall survival and spin echo CBV changes from T0 to T1 and from T2 to T3. (ACRIN 6686) VIII. To assess the association between overall survival and apparent diffusion coefficient (ADC) change from T0 to T1. (ACRIN 6686) IX. To assess the association between overall survival and ADC change from T1 to T2. (ACRIN 6686) X. To assess the association between progression-free survival and ADC change from T0 to T1. (ACRIN 6686) XI. To assess the association between progression-free survival and ADC change from T1 to T2. (ACRIN 6686) XII. To assess the association between T1 values of ADC and overall and progression-free survival. (ACRIN 6686) XIII. To assess the association between change in lesion size between T1 and T3, as measured by advanced magnetic resonance imaging (MRI), and overall and progression-free survival. (ACRIN 6686)

TERTIARY OBJECTIVES:

I. To determine the differential acute effects associated with the addition of bevacizumab to temozolomide and radiation, as compared to the conventional arm, on measures of neurocognitive function, health-related quality of life, and symptoms during radiation and across the longitudinal progression-free interval.

II. To determine the relationship of neurocognitive function, health-related quality of life, and symptoms, with progression-free and overall survival.

III. To determine the association between tumor molecular profile (i.e., mesenchymal/angiogenic phenotype and proneural phenotype) and neurocognitive function, health-related quality of life, and symptoms.

IV. To describe the association between health-related quality of life as measured by the European Organization for Research and Treatment Quality of Life Questionnaire-Core 30/Brain Cancer Module-20 (EORTC-QL30/BCM20) and mean symptom severity as measured by the M. D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) in patients enrolled in this study.

V. To evaluate the relationship between self-reported neurocognitive function and objectively measured tests of neurocognitive function (NCF).

VI. To assess the association between measures of change in enhancing tumor size at week 22 and overall survival in participants with glioma receiving chemoradiotherapy with and without bevacizumab.

VII. To assess the association between measures of change in T2-based tumor size at week 22 and overall survival in participants with glioma receiving chemoradiotherapy with and without bevacizumab.

VIII. To assess the association between changes in ADC values and overall survival in participants with glioma receiving chemoradiotherapy with and without bevacizumab.

OUTLINE: Patients are randomized to 1 of 2 treatment arms (there are also two registration steps prior to randomization which are labeled as "arms" in ClinicalTrials.gov to facilitate entry of results into the website).

ARM I: Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide orally (PO) once daily (QD) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.

ARM II: Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.

After completion of study treatment, patients are followed up every 3 months for 1 year, every 4 months for 1 year, and then every 6 months thereafter.

Conditions

Glioblastoma; Gliosarcoma; Supratentorial Glioblastoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Arm I (radiation therapy, temozolomide, placebo)

Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide PO QD for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.

Group Type: ACTIVE_COMPARATOR

3-Dimensional Conformal Radiation Therapy

Intervention Type: RADIATION

Undergo 3-dimentional conformal radiation therapy

Intensity-Modulated Radiation Therapy

Intervention Type: RADIATION

Undergo intensity-modulated radiation therapy

Laboratory Biomarker Analysis

Intervention Type: OTHER

Correlative studies

Placebo

Intervention Type: OTHER

Given IV

Quality-of-Life Assessment

Intervention Type: OTHER

Ancillary studies

Temozolomide

Intervention Type: DRUG

Given orally

Arm II (radiation therapy, temozolomide, bevacizumab)

Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.

Group Type: EXPERIMENTAL

3-Dimensional Conformal Radiation Therapy

Intervention Type: RADIATION

Undergo 3-dimentional conformal radiation therapy

Bevacizumab

Intervention Type: BIOLOGICAL

Given IV

Intensity-Modulated Radiation Therapy

Intervention Type: RADIATION

Undergo intensity-modulated radiation therapy

Laboratory Biomarker Analysis

Intervention Type: OTHER

Correlative studies

Quality-of-Life Assessment

Intervention Type: OTHER

Ancillary studies

Temozolomide

Intervention Type: DRUG

Given orally

Interventions

3-Dimensional Conformal Radiation Therapy

Undergo 3-dimentional conformal radiation therapy

Intervention Type: RADIATION

Bevacizumab

Given IV

Intervention Type: BIOLOGICAL

Intensity-Modulated Radiation Therapy

Undergo intensity-modulated radiation therapy

Intervention Type: RADIATION

Laboratory Biomarker Analysis

Correlative studies

Intervention Type: OTHER

Placebo

Given IV

Intervention Type: OTHER

Quality-of-Life Assessment

Ancillary studies

Intervention Type: OTHER

Temozolomide

Given orally

Intervention Type: DRUG

Other Intervention Names

3-dimensional radiation therapy; 3D CONFORMAL RADIATION THERAPY; 3D CRT; 3D-CRT; Conformal Therapy; Radiation Conformal Therapy; Anti-VEGF; Anti-VEGF Humanized Monoclonal Antibody; Anti-VEGF rhuMAb; Avastin; Bevacizumab Biosimilar BEVZ92; Bevacizumab Biosimilar BI 695502; Bevacizumab Biosimilar CBT 124; Bevacizumab Biosimilar FKB238; BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED; Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer; Recombinant Humanized Anti-VEGF Monoclonal Antibody; rhuMab-VEGF; IMRT; Intensity Modulated RT; Intensity-Modulated Radiotherapy; placebo therapy; PLCB; sham therapy; Quality of Life Assessment; CCRG-81045; Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-; M & B 39831; M and B 39831; Methazolastone; RP-46161; SCH 52365; Temcad; Temodal; Temodar; Temomedac

Eligibility Criteria

Inclusion Criteria

• Histologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization [WHO] grade IV) confirmed by central review prior to step 2 registration
• Tumor tissue that is determined by central pathology review prior to step 2 registration to be of sufficient size for analysis of O-6-methylguanine-DNA methyltransferase (MGMT) and determination of molecular profile

• Patients must have at least 1 block of tumor tissue; submission of 2 blocks is strongly encouraged to maximize the chances of eligibility; at least 1 cubic centimeter of tissue composed primarily of tumor must be present
• CUSA (Cavitron ultrasonic aspirator)-derived material is not allowed; fresh frozen tumor tissue acquisition is encouraged
• Diagnosis must be made by surgical excision, either partial or complete; stereotactic biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
• The tumor tissue should be sent as soon as possible to maximize the likelihood of eligibility; tumor tissue should be submitted by 4 weeks after the surgical procedure so that the study registration and treatment can commence by the mandatory 5 week post-surgery outer limit
• Sites must submit tissue fir central review in order to obtain the MGMT analysis; patients from sites not following protocol-specified process for obtaining MGMT results will be made ineligible
• The tumor must have a supratentorial component
• History/physical examination within 14 days prior to step 2 registration
• The patient must have recovered from the effects of surgery, postoperative infection, and other complications before step 2 registration
• A diagnostic contrast-enhanced MRI of the brain must be performed preoperatively and postoperatively prior to the initiation of radiotherapy; the postoperative scan must be performed within 28 days prior to step 1 registration

• An MRI or computed tomography (CT) scan (potentially in addition to the postoperative scan) must be obtained within 10 days prior to the start of radiation therapy and must not demonstrate significant postoperative hemorrhage defined as > 1 cm diameter of blood; if > 1 cm of acute blood is detected, the patient will be ineligible for this trial; the radiation planning MRI or CT scan may be used to determine presence of hemorrhage
• Patients unable to undergo MR imaging because of non-compatible devices can be enrolled, provided pre- and postoperative contrast-enhanced CT scans are obtained and are of sufficient quality; preoperative and postoperative scans must be the same type; such patients cannot be enrolled into the advanced imaging component
• Documentation of steroid doses within 14 days prior to step 2 registration
• Karnofsky performance status >= 70
• Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
• Platelets >= 100,000 cells/mm^3
• Hemoglobin >= 10.0 g/dL (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable)
• Blood urea nitrogen (BUN) =< 30 mg/dL within 14 days prior to step 2 registration
• Creatinine =< 1.7 mg/dl within 14 days prior to step 2 registration
• Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio; for UPC ratio > 0.5, 24-hour urine protein should be obtained and the level should be < 1000 mg
• Bilirubin =< 2.0 mg/dl within 14 days prior to step 2 registration
• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3 x normal range within 14 days prior to step 2 registration
• Systolic blood pressure =< 160 mg Hg or diastolic pressure =< 90 mm Hg within 14 days prior to step 2 registration
• Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior to step 2 registration
• Prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to step 2 registration
• Patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:

• No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
• In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of LMW heparin
• Patient must provide study specific informed consent prior to study entry
• Women of childbearing potential and male participants must practice adequate contraception
• For females of child-bearing potential, negative serum pregnancy test within 14 days prior to step 2 registration

Exclusion Criteria

• Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for >= 3 years; (for example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible)
• Recurrent or multifocal malignant gliomas
• Metastases detected below the tentorium or beyond the cranial vault
• Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable, except prior temozolomide or bevacizumab; prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted
• Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
• Severe, active co-morbidity, defined as follows:

• Unstable angina and/or congestive heart failure within the last 6 months
• Transmural myocardial infarction within the last 6 months
• Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 14 days of step 2 registration
• New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to step 2 registration
• History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months
• Serious and inadequately controlled cardiac arrhythmia
• Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease
• Evidence of bleeding diathesis or coagulopathy
• Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to step 2 registration, with the exception of the craniotomy for tumor resection
• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 2 registration
• Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
• Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control (CDC) definition; note, however, that HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive
• Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
• Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy
• Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
• Pregnant or lactating women
• Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
• For American College of Radiology Imaging Network (ACRIN) 6686 Advanced Imaging: inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Radiation Therapy Oncology Group

NETWORK

Sponsor Role: collaborator

NRG Oncology

OTHER

Sponsor Role: collaborator

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Gilbert

Role: PRINCIPAL_INVESTIGATOR

NRG Oncology

Locations

Providence Hospital

Mobile, Alabama, United States

Providence Alaska Medical Center

Anchorage, Alaska, United States

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Arizona Oncology Services Foundation

Scottsdale, Arizona, United States

Arizona Oncology Associates-West Orange Grove

Tucson, Arizona, United States

Sutter Cancer Centers Radiation Oncology Services-Auburn

Auburn, California, United States

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, United States

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Cameron Park, California, United States

Mercy San Juan Medical Center

Carmichael, California, United States

John Muir Medical Center-Concord Campus

Concord, California, United States

City of Hope Comprehensive Cancer Center

Duarte, California, United States

California Cancer Center - North Fresno

Fresno, California, United States

Cancer Care Associates of Fresno Medical Group Inc

Fresno, California, United States

Saint Jude Medical Center

Fullerton, California, United States

UC San Diego Moores Cancer Center

La Jolla, California, United States

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

Memorial Medical Center

Modesto, California, United States

Bay Area Tumor Institute

Oakland, California, United States

Kaiser Permanente Oakland-Broadway

Oakland, California, United States

Saint Joseph Hospital - Orange

Orange, California, United States

Pomona Valley Hospital Medical Center

Pomona, California, United States

Kaiser Permanente-Rancho Cordova Cancer Center

Rancho Cordova, California, United States

Rohnert Park Cancer Center

Rohnert Park, California, United States

Sutter Cancer Centers Radiation Oncology Services-Roseville

Roseville, California, United States

The Permanente Medical Group-Roseville Radiation Oncology

Roseville, California, United States

Sutter Medical Center Sacramento

Sacramento, California, United States

Mercy General Hospital Radiation Oncology Center

Sacramento, California, United States

South Sacramento Cancer Center

Sacramento, California, United States

University of California San Diego

San Diego, California, United States

California Pacific Medical Center-Pacific Campus

San Francisco, California, United States

Kaiser Permanente Medical Center - Santa Clara

Santa Clara, California, United States

Kaiser Permanente Cancer Treatment Center

South San Francisco, California, United States

Sutter Cancer Centers Radiation Oncology Services-Vacaville

Vacaville, California, United States

John Muir Medical Center-Walnut Creek

Walnut Creek, California, United States

Rocky Mountain Cancer Centers-Aurora

Aurora, Colorado, United States

Boulder Community Hospital

Boulder, Colorado, United States

Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, United States

Porter Adventist Hospital

Denver, Colorado, United States

Swedish Medical Center

Englewood, Colorado, United States

Poudre Valley Hospital

Fort Collins, Colorado, United States

Rocky Mountain Cancer Centers-Littleton

Littleton, Colorado, United States

North Suburban Medical Center

Thornton, Colorado, United States

SCL Health Lutheran Medical Center

Wheat Ridge, Colorado, United States

Saint Vincent's Medical Center

Bridgeport, Connecticut, United States

Hartford Hospital

Hartford, Connecticut, United States

The Hospital of Central Connecticut

New Britain, Connecticut, United States

Yale University

New Haven, Connecticut, United States

William Backus Hospital

Norwich, Connecticut, United States

Broward Health Medical Center

Fort Lauderdale, Florida, United States

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Hollywood, Florida, United States

Baptist MD Anderson Cancer Center

Jacksonville, Florida, United States

Integrated Community Oncology Network-Southside Cancer Center

Jacksonville, Florida, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Baptist Medical Center South

Jacksonville, Florida, United States

Integrated Community Oncology Network-Florida Cancer Center Beaches

Jacksonville Beach, Florida, United States

Baptist Hospital of Miami

Miami, Florida, United States

Mount Sinai Medical Center

Miami Beach, Florida, United States

21st Century Oncology-Orange Park

Orange Park, Florida, United States

Florida Hospital Orlando

Orlando, Florida, United States

UF Cancer Center at Orlando Health

Orlando, Florida, United States

21st Century Oncology-Palatka

Palatka, Florida, United States

Sacred Heart Hospital

Pensacola, Florida, United States

Integrated Community Oncology Network-Flager Cancer Center

Saint Augustine, Florida, United States

Robert and Carol Weissman Cancer Center at Martin Health

Stuart, Florida, United States

Piedmont Hospital

Atlanta, Georgia, United States

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States

John B Amos Cancer Center

Columbus, Georgia, United States

Dekalb Medical Center

Decatur, Georgia, United States

Northeast Georgia Medical Center-Gainesville

Gainesville, Georgia, United States

Southern Regional Medical Center

Riverdale, Georgia, United States

Memorial University Medical Center

Savannah, Georgia, United States

University of Hawaii Cancer Center

Honolulu, Hawaii, United States

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, United States

Northwest Community Hospital

Arlington Heights, Illinois, United States

Northwestern University

Chicago, Illinois, United States

John H Stroger Jr Hospital of Cook County

Chicago, Illinois, United States

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, United States

Decatur Memorial Hospital

Decatur, Illinois, United States

Ingalls Memorial Hospital

Harvey, Illinois, United States

Loyola University Medical Center

Maywood, Illinois, United States

Trinity Medical Center

Moline, Illinois, United States

Edward Hospital/Cancer Center

Naperville, Illinois, United States

Advocate Lutheran General Hospital

Park Ridge, Illinois, United States

Methodist Medical Center of Illinois

Peoria, Illinois, United States

Memorial Medical Center

Springfield, Illinois, United States

IU Health Bloomington

Bloomington, Indiana, United States

Radiation Oncology Associates PC

Fort Wayne, Indiana, United States

Parkview Hospital Randallia

Fort Wayne, Indiana, United States

IU Health Methodist Hospital

Indianapolis, Indiana, United States

Community Cancer Center East

Indianapolis, Indiana, United States

IU Health Central Indiana Cancer Centers-East

Indianapolis, Indiana, United States

Community Cancer Center North

Indianapolis, Indiana, United States

Saint Vincent Hospital and Health Care Center

Indianapolis, Indiana, United States

IU Health Ball Memorial Hospital

Muncie, Indiana, United States

Northern Indiana Cancer Research Consortium

South Bend, Indiana, United States

McFarland Clinic PC-William R Bliss Cancer Center

Ames, Iowa, United States

Physicians' Clinic of Iowa PC

Cedar Rapids, Iowa, United States

Iowa Methodist Medical Center

Des Moines, Iowa, United States

Mercy Medical Center - Des Moines

Des Moines, Iowa, United States

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, United States

Mercy Medical Center - North Iowa

Mason City, Iowa, United States

University of Kansas Cancer Center

Kansas City, Kansas, United States

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, United States

Kansas City NCI Community Oncology Research Program

Prairie Village, Kansas, United States

Via Christi Regional Medical Center

Wichita, Kansas, United States

Wesley Medical Center

Wichita, Kansas, United States

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, United States

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, United States

Ochsner Medical Center Jefferson

New Orleans, Louisiana, United States

Louisiana State University Health Sciences Center Shreveport

Shreveport, Louisiana, United States

Central Maine Medical Center

Lewiston, Maine, United States

Maine Medical Center- Scarborough Campus

Scarborough, Maine, United States

Anne Arundel Medical Center

Annapolis, Maryland, United States

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, United States

Saint Agnes Hospital

Baltimore, Maryland, United States

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Saint Anne's Hospital

Fall River, Massachusetts, United States

Cape Cod Hospital

Hyannis, Massachusetts, United States

Lowell General Hospital

Lowell, Massachusetts, United States

D'Amour Center for Cancer Care

Springfield, Massachusetts, United States

Saint Joseph Mercy Hospital

Ann Arbor, Michigan, United States

Beaumont Hospital-Dearborn

Dearborn, Michigan, United States

Saint John Hospital and Medical Center

Detroit, Michigan, United States

Genesys Regional Medical Center-West Flint Campus

Flint, Michigan, United States

West Michigan Cancer Center

Kalamazoo, Michigan, United States

Sparrow Hospital

Lansing, Michigan, United States

William Beaumont Hospital-Royal Oak

Royal Oak, Michigan, United States

Saint Mary's of Michigan

Saginaw, Michigan, United States

Saint John Macomb-Oakland Hospital

Warren, Michigan, United States

Sanford Clinic North-Bemidgi

Bemidji, Minnesota, United States

Fairview Ridges Hospital

Burnsville, Minnesota, United States

Mercy Hospital

Coon Rapids, Minnesota, United States

Saint Luke's Hospital of Duluth

Duluth, Minnesota, United States

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, United States

Abbott-Northwestern Hospital

Minneapolis, Minnesota, United States

North Memorial Medical Health Center

Robbinsdale, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

Coborn Cancer Center at Saint Cloud Hospital

Saint Cloud, Minnesota, United States

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, United States

Regions Hospital

Saint Paul, Minnesota, United States

United Hospital

Saint Paul, Minnesota, United States

Ridgeview Medical Center

Waconia, Minnesota, United States

Singing River Hospital

Pascagoula, Mississippi, United States

Cape Radiation Oncology

Cape Girardeau, Missouri, United States

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, United States

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, United States

Truman Medical Center

Kansas City, Missouri, United States

The University of Kansas Cancer Center-South

Kansas City, Missouri, United States

The University of Kansas Cancer Center-North

Kansas City, Missouri, United States

Washington University School of Medicine

St Louis, Missouri, United States

Billings Clinic Cancer Center

Billings, Montana, United States

CHI Health Good Samaritan

Kearney, Nebraska, United States

Saint Elizabeth Regional Medical Center

Lincoln, Nebraska, United States

Nebraska Methodist Hospital

Omaha, Nebraska, United States

Alegent Health Immanuel Medical Center

Omaha, Nebraska, United States

Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Nevada Cancer Research Foundation CCOP

Las Vegas, Nevada, United States

Renown Regional Medical Center

Reno, Nevada, United States

Concord Hospital

Concord, New Hampshire, United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Elliot Hospital

Manchester, New Hampshire, United States

Saint Barnabas Medical Center

Livingston, New Jersey, United States

Monmouth Medical Center

Long Branch, New Jersey, United States

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

New Brunswick, New Jersey, United States

Riverview Medical Center/Booker Cancer Center

Red Bank, New Jersey, United States

Sparta Cancer Treatment Center

Sparta, New Jersey, United States

Lovelace Medical Center-Downtown

Albuquerque, New Mexico, United States

University of New Mexico Cancer Center

Albuquerque, New Mexico, United States

New Mexico Oncology Hematology Consultants

Albuquerque, New Mexico, United States

New York Oncology Hematology PC - Albany

Albany, New York, United States

Maimonides Medical Center

Brooklyn, New York, United States

Sands Cancer Center

Canandaigua, New York, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

South Nassau Communities

Oceanside, New York, United States

Hudson Valley Oncology Associates

Poughkeepsie, New York, United States

Highland Hospital

Rochester, New York, United States

University Radiation Oncology

Rochester, New York, United States

University of Rochester

Rochester, New York, United States

Stony Brook University Medical Center

Stony Brook, New York, United States

State University of New York Upstate Medical University

Syracuse, New York, United States

Montefiore Medical Center - Moses Campus

The Bronx, New York, United States

Mission Hospital-Memorial Campus

Asheville, North Carolina, United States

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, United States

Novant Health Presbyterian Medical Center

Charlotte, North Carolina, United States

Margaret R Pardee Memorial Hospital

Hendersonville, North Carolina, United States

FirstHealth of the Carolinas-Moore Regional Hosiptal

Pinehurst, North Carolina, United States

Duke Women's Cancer Care Raleigh

Raleigh, North Carolina, United States

Novant Health Forsyth Medical Center

Winston-Salem, North Carolina, United States

Southeast Clinical Oncology Research (SCOR) Consortium NCORP

Winston-Salem, North Carolina, United States

Sanford Broadway Medical Center

Fargo, North Dakota, United States

Summa Akron City Hospital/Cooper Cancer Center

Akron, Ohio, United States

Akron General Medical Center

Akron, Ohio, United States

Summa Barberton Hospital

Barberton, Ohio, United States

UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, United States

Mercy Medical Center

Canton, Ohio, United States

Aultman Health Foundation

Canton, Ohio, United States

University of Cincinnati/Barrett Cancer Center

Cincinnati, Ohio, United States

Case Western Reserve University

Cleveland, Ohio, United States

MetroHealth Medical Center

Cleveland, Ohio, United States

Cleveland Clinic Cancer Center/Fairview Hospital

Cleveland, Ohio, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Riverside Methodist Hospital

Columbus, Ohio, United States

Grant Medical Center

Columbus, Ohio, United States

The Mark H Zangmeister Center

Columbus, Ohio, United States

Toledo Clinic Cancer Centers-Maumee

Maumee, Ohio, United States

Hillcrest Hospital Cancer Center

Mayfield Heights, Ohio, United States

Lake University Ireland Cancer Center

Mentor, Ohio, United States

Southwest General Health Center Ireland Cancer Center

Middleburg Heights, Ohio, United States

Saint Charles Hospital

Oregon, Ohio, United States

Cancer Care Center, Incorporated

Salem, Ohio, United States

North Coast Cancer Care

Sandusky, Ohio, United States

Trinity's Tony Teramana Cancer Center

Steubenville, Ohio, United States

Flower Hospital

Sylvania, Ohio, United States

Mercy Saint Anne Hospital

Toledo, Ohio, United States

University Pointe

West Chester, Ohio, United States

UHHS-Westlake Medical Center

Westlake, Ohio, United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Natalie Warren Bryant Cancer Center at Saint Francis

Tulsa, Oklahoma, United States

Willamette Valley Cancer Center

Eugene, Oregon, United States

Legacy Good Samaritan Hospital and Medical Center

Portland, Oregon, United States

Providence Portland Medical Center

Portland, Oregon, United States

Providence Saint Vincent Medical Center

Portland, Oregon, United States

Salem Hospital

Salem, Oregon, United States

Abington Memorial Hospital

Abington, Pennsylvania, United States

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, United States

UPMC-Heritage Valley Health System Beaver

Beaver, Pennsylvania, United States

Saint Luke's University Hospital-Bethlehem Campus

Bethlehem, Pennsylvania, United States

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, United States

Geisinger Medical Center

Danville, Pennsylvania, United States

Northeast Radiation Oncology Center

Dunmore, Pennsylvania, United States

Pocono Medical Center

East Stroudsburg, Pennsylvania, United States

The Regional Cancer Center

Erie, Pennsylvania, United States

Fox Chase Cancer Center Buckingham

Furlong, Pennsylvania, United States

Adams Cancer Center

Gettysburg, Pennsylvania, United States

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, United States

Cherry Tree Cancer Center

Hanover, Pennsylvania, United States

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, United States

UPMC-Johnstown/John P. Murtha Regional Cancer Center

Johnstown, Pennsylvania, United States

Armstrong Center for Medicine and Health

Kittanning, Pennsylvania, United States

Lancaster General Hospital

Lancaster, Pennsylvania, United States

UPMC Cancer Center at UPMC McKeesport

McKeesport, Pennsylvania, United States

Intercommunity Cancer Center

Monroeville, Pennsylvania, United States

Allegheny Valley Hospital

Natrona Heights, Pennsylvania, United States

UPMC Jameson

New Castle, Pennsylvania, United States

Paoli Memorial Hospital

Paoli, Pennsylvania, United States

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Aria Health-Torresdale Campus

Philadelphia, Pennsylvania, United States

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, United States

UPMC Jefferson Regional Radiation Oncology

Pittsburgh, Pennsylvania, United States

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, United States

UPMC Cancer Center at UPMC Northwest

Seneca, Pennsylvania, United States

UPMC Washington Hospital Radiation Oncology

Washington, Pennsylvania, United States

Reading Hospital

West Reading, Pennsylvania, United States

Lankenau Medical Center

Wynnewood, Pennsylvania, United States

WellSpan Health-York Hospital

York, Pennsylvania, United States

Rhode Island Hospital

Providence, Rhode Island, United States

Spartanburg Medical Center

Spartanburg, South Carolina, United States

Rapid City Regional Hospital

Rapid City, South Dakota, United States

Sanford Cancer Center-Oncology Clinic

Sioux Falls, South Dakota, United States

Erlanger Medical Center

Chattanooga, Tennessee, United States

Jackson-Madison County General Hospital

Jackson, Tennessee, United States

Thompson Cancer Survival Center

Knoxville, Tennessee, United States

Texas Oncology-Arlington South

Arlington, Texas, United States

Texas Oncology Bedford

Bedford, Texas, United States

Saint Joseph Regional Cancer Center

Bryan, Texas, United States

Texas Oncology Methodist Charlton Cancer Center

Dallas, Texas, United States

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, United States

Texas Oncology-Denton South

Denton, Texas, United States

The Klabzuba Cancer Center

Fort Worth, Texas, United States

University of Texas Medical Branch

Galveston, Texas, United States

M D Anderson Cancer Center

Houston, Texas, United States

Texas Oncology-Longview Cancer Center

Longview, Texas, United States

Covenant Medical Center-Lakeside

Lubbock, Texas, United States

West Texas Cancer Center

Odessa, Texas, United States

University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

Texas Cancer Center-Sherman

Sherman, Texas, United States

Texas Oncology Cancer Center Sugar Land

Sugar Land, Texas, United States

Tyler Cancer Center

Tyler, Texas, United States

Intermountain Medical Center

Murray, Utah, United States

McKay-Dee Hospital Center

Ogden, Utah, United States

Utah Valley Regional Medical Center

Provo, Utah, United States

Utah Cancer Specialists-Salt Lake City

Salt Lake City, Utah, United States

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, United States

LDS Hospital

Salt Lake City, Utah, United States

Dixie Medical Center Regional Cancer Center

St. George, Utah, United States

University of Vermont Medical Center

Burlington, Vermont, United States

Inova Alexandria Hospital

Alexandria, Virginia, United States

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Naval Medical Center - Portsmouth

Portsmouth, Virginia, United States

PeaceHealth Saint Joseph Medical Center

Bellingham, Washington, United States

Harrison Medical Center

Bremerton, Washington, United States

Virginia Mason Medical Center

Seattle, Washington, United States

Swedish Medical Center-First Hill

Seattle, Washington, United States

Cancer Care Northwest - Spokane South

Spokane, Washington, United States

PeaceHealth Southwest Medical Center

Vancouver, Washington, United States

Compass Oncology Vancouver

Vancouver, Washington, United States

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Yakima, Washington, United States

Wheeling Hospital/Schiffler Cancer Center

Wheeling, West Virginia, United States

Langlade Hospital and Cancer Center

Antigo, Wisconsin, United States

Radiology Associates of Appleton/ThedaCare Regional Medical Center

Appleton, Wisconsin, United States

Marshfield Clinic Cancer Center at Sacred Heart

Eau Claire, Wisconsin, United States

Sacred Heart Hospital

Eau Claire, Wisconsin, United States

Bellin Memorial Hospital

Green Bay, Wisconsin, United States

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, United States

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, United States

UW Cancer Center Johnson Creek

Johnson Creek, Wisconsin, United States

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, United States

Dean Hematology and Oncology Clinic

Madison, Wisconsin, United States

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Bay Area Medical Center

Marinette, Wisconsin, United States

Marshfield Clinic

Marshfield, Wisconsin, United States

Marshfield Medical Center

Marshfield, Wisconsin, United States

Froedtert and the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Marshfield Clinic-Minocqua Center

Minocqua, Wisconsin, United States

Saint Michael's Hospital

Stevens Point, Wisconsin, United States

ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, United States

Aspirus Regional Cancer Center

Wausau, Wisconsin, United States

Diagnostic and Treatment Center

Weston, Wisconsin, United States

Marshfield Clinic - Weston Center

Weston, Wisconsin, United States

Aspirus UW Cancer Center

Wisconsin Rapids, Wisconsin, United States

Doctor H. Bliss Murphy Cancer Centre

St. John's, Newfoundland and Labrador, Canada

Health Sciences North

Greater Sudbury, Ontario, Canada

CHUM - Hopital Notre-Dame

Montreal, Quebec, Canada

McGill University Department of Oncology

Montreal, Quebec, Canada

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Countries

United States; Canada; Israel

References

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.

Reference Type: DERIVED

PMID: 24552317 (View on PubMed)

Other Identifiers

NCI-2009-01670

Identifier Type: REGISTRY

Identifier Source: secondary_id

RTOG-0825

Identifier Type: -

Identifier Source: secondary_id

RTOG 0825

Identifier Type: -

Identifier Source: secondary_id

CDR0000640428

Identifier Type: -

Identifier Source: secondary_id

RTOG-0825

Identifier Type: OTHER

Identifier Source: secondary_id

RTOG-0825

Identifier Type: OTHER

Identifier Source: secondary_id

U10CA180868

Identifier Type: NIH

Identifier Source: secondary_id

View Link

U10CA021661

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2009-01670

Identifier Type: -

Identifier Source: org_study_id